HeartSciences Inc. (HSCSW)
| Market Cap | 12.83M +241.2% |
| Revenue (ttm) | 4,519 -76.6% |
| Net Income | -10.26M |
| EPS | -3.19 |
| Shares Out | 4.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 0.0680 |
| Day's Range | n/a |
| 52-Week Range | 0.0349 - 0.1439 |
| Beta | 1.78 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 14, 2026 |
About HSCSW
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic EC... [Read more]
News
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 15, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences gets FDA clearance for MyoVista wavECG device
HeartSciences (HSCS) announced that the FDA has granted 510 clearance for its MyoVista wavECG device as a 12-lead resting electrocardiograph. The clearance covers the acquisition and interpretation of...
HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device
Southlake, TX, Oct. 06, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing e...
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 2, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 30, 2026, providing details for shareholder voting and corporate governance matters.
Fortitude Appoints Kimberly Pittman as Chief Legal Officer
FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude Mining Holdings, Inc. (“Fortitude” or the “Company”), a vertically-integrated digital asset mining platform anchored in Zcash, today announced the appointmen...
HeartSciences files $200M mixed securities shelf
17:02 EDT HeartSciences (HSCS) files $200M mixed securities shelf
HeartSciences Registration statement: Registration filing
HeartSciences filed a registration statement on September 25, 2026, providing details about a securities offering with the SEC.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 24, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 21, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 17, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 17, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 16, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Proposed business combination with Fortitude, a vertically-integrated digital asset mining platform anchored in Zcash, continues to progress, with closing expected in Q4 calendar 2026
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 15, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 15, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 14, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Quarterly report: Q1 2027
HeartSciences has published its Q1 2027 quarterly earnings report on September 14, 2026.
HeartSciences Earnings release: Q1 2027
HeartSciences released its Q1 2027 earnings on September 14, 2026, summarizing the period's financial results.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on September 11, 2026, providing details for shareholder voting and corporate governance matters.